LAE120 / Laekna Therap - LARVOL DELTA

Preclinical candidate LAE120, a novel selective USP1 inhibitor shows effective anticancer and combination activity with PARP inhibitor (AACR 2024) - "The combination of LAE120 and Olaparib (PARP inhibitor) yielded a more robust and durable anti-tumor efficacy at low dose (TGI: 110%, LAE120, 5 mg/kg BID + Olaparib, 50 mg/kg QD). Preclinical-tox studies indicated the molecule was well tolerated without significant toxicities and hematological observations. Both in vitro and in vivo data strongly support further investigation of LAE120, whether as a single agent or in combination therapy."

Preclinical • Breast Cancer • Oncology • Solid Tumor • ABL1 • BCR • BRCA • BRCA1 • BRCA2 • HRD • USP1

Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA (Businesswire) - "Laekna...announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120...for the treatment of advanced solid tumors. LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers....LAE120 shows robust tumor inhibitory activity across various xenograft models such as MDA-MB-436 and K562 as a single agent and exhibits synergistic effect in combination with PARP inhibitors. It also demonstrates good therapeutic windows in GLP long-term toxicology study."

IND • Preclinical • Solid Tumor

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024 (PRNewswire) - "LAE120 shows robust tumor inhibitory activity in MDA-MB-436 and K562 xenograft models as a single agent and exhibits synergistic effect in combination with PARP inhibitors. LAE120 demonstrates good therapeutic window in DRF study and is currently at IND-enabling stage."

Preclinical • Breast Cancer • Oncology